Study Finds Pandemic Likely to Negatively Impact Biopharmaceutical Sector

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Threats to intellectual property, political pressure to lower prices, disruption of clinical trials will cause long-term harm

BOSTON – Contrary to conventional wisdom that says the coronavirus pandemic will generally benefit biopharmaceutical companies, a new Pioneer Institute study finds many companies will emerge from the pandemic commercially weaker, dealing with delays in new product launches and with fewer resources to invest in research and development.

“There will certainly be worldwide demand for COVID-19 treatments,” said William Smith, author of “The Negative Impact of COVID-19 Upon the Biopharmaceutical Sector.”  “But they will also require massive investments in clinical development and manufacturing, and political pressure on pricing makes it impossible for companies to recoup those investments.”

Cipro is an antibiotic well-suited to treat anthrax, which began arriving in mailboxes in the weeks after September 11, 2001.  The Centers for Disease Control recommends that patients exposed to the bacteria take Cipro twice a day for 60 days.  Despite the fact that the entire course of treatment would only cost $219, Bayer agreed to cut the price in half after the U.S. Secretary of Health and Human Services at that time threatened to take away the company’s patent.

More recently, when Gilead announced it would invest $1 billion in Remdesivir, a promising COVID-19 treatment, one would have thought the company’s stock would rise.  Instead, it fell 5 percent.  A number of analysts remarked that the reason was fears that political pressure would result in very low prices or threats to Gilead’s patent.

Some investors and industry leaders may conclude that investments in major public health emergencies should be avoided in favor of research on lifestyle treatments or medications for less serious conditions that aren’t accompanied by threats to intellectual property or pressure to reduce prices.

Political pressure to cut prices is likely to be most acute in the area of vaccines, where the federal government is providing grants to companies such as Johnson & Johnson and Moderna.  Many policymakers will likely see any new vaccine that emerges from research that was partially funded by the government as public property.

“There may be humanitarian reasons why companies choose not to profit from their treatments,” said Pioneer Executive Director Jim Stergios.  “But policymakers should also be aware that threats to intellectual property create significant disincentives to investment.”

In 2018, Massachusetts institutions received nearly $3 billion in National Institutes of Health funding, the second highest amount among the states.  That same year, private venture companies invested $4.8 billion in the Commonwealth’s life sciences companies.  In terms of new businesses, more than a third of U.S.-based biotechs that went public in the first half of 2019 were Massachusetts-based.

These companies also face delays in clinical trials for non-COVID-19 treatments, which could significantly disrupt long-term product pipelines.  Since firms typically file patents before clinical trials begin, significant delays eat up the period during which treatments can be sold under patent before opening up to competition from generic makers.

The delays are particularly damaging to small firms, whose future may depend on a successful trial.

Smith’s recommendations include extending patent life on products by the period clinical trials were delayed by the pandemic, and that COVID-19 treatments in which companies made significant investments should be priced to allow a reasonable return on that investment.

About the Author

Dr. William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute. He writes about public policy issues impacting the life sciences industry with particular emphasis upon pharmaceuticals. Dr. Smith has 25 years of experience in government and in corporate roles. He spent ten years at Pfizer as Vice President of Public Affairs and Policy. He later served as a consultant to major pharmaceutical, biotechnology and medical device companies, and was President of a small medical device company for three years. His career has also included senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Governor’s office in Massachusetts. He is affiliated as Research Fellow and Managing Director with the Center for the Study of Statesmanship at The Catholic University of America (CUA). He earned his PhD at CUA and a bachelor’s degree from Georgetown University.

About Pioneer

Mission
Pioneer Institute develops and communicates dynamic ideas that advance prosperity and a vibrant civic life in Massachusetts and beyond.

Vision
Success for Pioneer is when the citizens of our state and nation prosper and our society thrives because we enjoy world-class options in education, healthcare, transportation and economic opportunity, and when our government is limited, accountable and transparent.

Values
Pioneer believes that America is at its best when our citizenry is well-educated, committed to liberty, personal responsibility, and free enterprise, and both willing and able to test their beliefs based on facts and the free exchange of ideas.

Get Our COVID-19 News, Tips & Resources!

Related Content

Pulitzer Winner Taylor Branch on MLK, Civil Rights History, & Race in America

/
This week on “The Learning Curve," Cara and Gerard are joined by Taylor Branch, Pulitzer Prize-winning author of a landmark trilogy on the Civil Rights era, America in the King Years. They discuss the life and legacy of the Rev. Dr. Martin Luther King, whose birthday the nation observed on Monday. They review Dr. King’s powerful, moving oratory, drawing on spiritual and civic ideals to promote nonviolent protest against racial injustice, and how, as head of the Southern Christian Leadership Conference, he shared leadership of the movement with organizations such as the Student Nonviolent Coordinating Committee.

California Tax Experiment: Policy Makers Receive Valuable Economics Lesson

/
Host Joe Selvaggi talks with Stanford University Economics Professor Joshua Rauh about his research on the reaction of Californians to a tax increase, from his report, “The Behavioral Response to State Income Taxation of High Earners, Evidence from California.” Prof. Rauh shares how his research offers tax policy makers insight into the likely effects of similar increases in their own states, including here in Massachusetts.

New Study Finds Tax Policy Drives Connecticut’s Ongoing Fiscal & Economic Crisis

Multiple rounds of tax increases aimed at high earners and corporations triggered an exodus from Connecticut of large employers and wealthy individuals, according to a new study published by Pioneer Institute.

Eva Moskowitz of Success Academy on Charter Schools, Achievement Gaps, & COVID-19 Learning Loss

/
This week on “The Learning Curve," Cara and Gerard kick off the new year with Eva Moskowitz, CEO & Founder of Success Academy Charter Schools, a network of 47 schools enrolling 20,000 K-12 students in New York City. Eva shares her own education path, and how it influences her leadership and philosophy.

Unemployment Insurance Rescue: Employer Advocate Seeks Relief to Catalyze Pandemic Recovery

/
Joe Selvaggi talks with John Regan, President and CEO of Associated Industries of Massachusetts, about the impact of higher UI rates on employers and what legislators can do to help mitigate the pain.

USED Asst. Sec. Jim Blew Talks Sec. DeVos, School Choice, & K-12 Politics

/
This week on “The Learning Curve,” Cara and Gerard are joined by Jim Blew, the assistant secretary for planning, evaluation, and policy development at the U.S. Department of Education. Assistant Secretary Blew shares lessons from leading and implementing K-12 public education reform efforts in often contentious policy environments, and the unique challenges of the current partisanship and gridlock in Washington, D.C.

Oxford & UCLA Pulitzer Winner Prof. Daniel Walker Howe on Horace Mann, Common Schools, & Educating for Democracy

/
This week on “The Learning Curve,” Cara and Gerard are joined by Daniel Walker Howe, Rhodes Professor of American History Emeritus at Oxford University in England and Professor of History Emeritus at UCLA. Drawing from his Pulitzer Prize-winning book, What Hath God Wrought: The Transformation of America, 1815-1848, he provides background information on Horace Mann, the first secretary of the Massachusetts State Board of Education, founder of the common school movement in public education, and a prominent abolitionist in Congress.

COVID-19 Vaccine: The End of the Epidemic is Within Reach

/
Join Host Joe Selvaggi and Virologist and Investor Dr. Peter Kolchinsky as they discuss the rapid development, efficacy, and rollout of the newly approved COVID-19 vaccines.

Knowledge is Power: Sir Francis Bacon and the Scientific Method – 10 Resources for High School Students

In Pioneer’s ongoing series of blogs here, on curricular resources for parents, families, and teachers during COVID-19, this one focuses on: Celebrating the 400th Anniversary of Sir Francis Bacon and the scientific method.

Stanford’s Prof. Caroline Hoxby on Charter Schools, K-12 Ed Reform, & Global Competitiveness

/
This week on “The Learning Curve,” Cara and Gerard are joined by Caroline Hoxby, the Scott and Donya Bommer Professor of Economics at Stanford University and a Senior Fellow of the Hoover Institution.

The 400th Anniversary of the Mayflower – 15 Resources for K-12 Students

In Pioneer’s ongoing series of blogs on curricular resources for parents, families, and teachers during COVID-19, this one focuses on: Celebrating the 400th Anniversary of the Mayflower’s voyage.

SABIS® President Carl Bistany on International Education, Charter Public Schools, & At-Risk Students

/
This week on “The Learning Curve,” Cara and Gerard are joined by Carl Bistany, the president of SABIS® Educational Systems, an education company founded over 130 years ago that serves young women in the Middle East, and poor and minority students in the U.S.